Carnitine and Cardiac Dysfunction in Childhood Cancer Survivors Treated with Anthracyclines
Authors:
- Saro H. ArmenianSASaro H. Armenian
- Sarah K. GelehrterSGSarah K. Gelehrter
- Tabitha VaseTVTabitha Vase
- Rajkumar VenkatramaniRVRajkumar Venkatramani
- Wendy LandierWLWendy Landier
- Karla D. WilsonKWKarla D. Wilson
- Claudia HerreraCHClaudia Herrera
- Leah ReichmanLRLeah Reichman
- John-David MenteerJMJohn-David Menteer
- Leo MascarenhasLMLeo Mascarenhas
- David R. FreyerDFDavid R. Freyer
- Kalyanasundaram VenkataramanKVKalyanasundaram Venkataraman
Open Access
- 1 June 2014
- journal article
- research article
- Published by American Association for Cancer Research (AACR) in Cancer Epidemiology, Biomarkers & Prevention
- Vol. 23 (6) , 1109-1114
Abstract
Childhood cancer survivors are at high risk of developing congestive heart failure (CHF) compared with the general population, and there is a dose-dependent increase in CHF risk by anthracycline dose. The mechanism by which this occurs has not been fully elucidated. Metabolomics, the comprehensive profile of small-molecule metabolites, has the potential to provide insight into the pathogenesis of disease states and discover diagnostic markers for therapeutic targets. We performed echocardiographic testing and blood plasma metabolomic analyses (8 pathways; 354 metabolites) in 150 asymptomatic childhood cancer survivors previously treated with anthracyclines. Median time from cancer diagnosis to study participation was 12.4 years (2.6–37.9 years); 64% were treated for a hematologic malignancy; median anthracycline dose was 350 mg/m2 (25–642 mg/m2). Thirty-five (23%) participants had cardiac dysfunction—defined as left ventricular end-systolic wall stress >2SD by echocardiogram. Plasma levels of 15 compounds in three metabolic pathways (carbohydrate, amino acid, and lipid metabolism) were significantly different between individuals with cardiac dysfunction and those with normal systolic function. After adjusting for multiple comparisons, individuals with cardiac dysfunction had significantly lower plasma carnitine levels [relative ratio (RR), 0.89; P < 0.01] in relation to those with normal systolic function. These findings may facilitate the development of primary prevention (treatment of carnitine deficiency before/during anthracycline administration) and secondary prevention strategies (screening and treatment in long-term survivors) in patients at highest risk for CHF. Cancer Epidemiol Biomarkers Prev; 23(6); 1109–14. ©2014 AACR.Keywords
All Related Versions
This publication has 26 references indexed in Scilit:
- Metabolomics as a tool for cardiac researchNature Reviews Cardiology, 2011
- Carnitine levels and cardiac functions in children with solid malignancies receiving doxorubicin therapyIndian Journal of Medical and Paediatric Oncology, 2011
- Inhibition of gene expression of heart fatty acid binding protein and organic cation/carnitine transporter in doxorubicin cardiomyopathic rat modelEuropean Journal of Pharmacology, 2010
- Role of carnitine in diseaseNutrition & Metabolism, 2010
- Monitoring for Cardiovascular Disease in Survivors of Childhood Cancer: Report From the Cardiovascular Disease Task Force of the Children's Oncology GroupPediatrics, 2008
- Noninvasive Evaluation of Late Anthracycline Cardiac Toxicity in Childhood Cancer SurvivorsJournal of Clinical Oncology, 2007
- Pathophysiology of anthracycline‐ and radiation‐associated cardiomyopathies: Implications for screening and preventionPediatric Blood & Cancer, 2005
- Statistical significance for genomewide studiesProceedings of the National Academy of Sciences, 2003
- Underlying Causes and Long-Term Survival in Patients with Initially Unexplained CardiomyopathyNew England Journal of Medicine, 2000
- Effects of l-carnitine administration on left ventricular remodeling after acute anterior myocardial infarction: the l-Carnitine Ecocardiografia Digitalizzata Infarto Miocardico (CEDIM) trialJACC, 1995